Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Revenue projections:

Revenue projections for CIPLA
Revenue projections for CIPLA

CIPLA is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 0.000000
forwardPE 23.584126
debtToEquity 1.404000
earningsGrowth 0.102000
revenueGrowth 0.032000
grossMargins 0.666910
operatingMargins 0.223110
trailingEps 66.760000
forwardEps 63.540000

CIPLA's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
With positive gross and operating margins, CIPLA demonstrates its profitability and efficiency. These metrics show that the company is managing costs well while generating strong revenue, highlighting robust financial health.
CIPLA's lower forward EPS compared to its trailing EPS indicates that the company may be less profitable in the upcoming year. This suggests a potential slowdown in earnings, which could be a sign of weaker financial performance ahead.

Price projections:

Price projections for CIPLA
Price projections for CIPLA

CIPLA's price projections have been consistently revised upward, suggesting that analysts are becoming increasingly optimistic about the company's future. This trend reflects confidence in CIPLA's ability to achieve strong financial results.

Insider Transactions:

Insider Transactions for CIPLA
Insider Transactions for CIPLA


Recent trading of Cipla Limited stock saw 2 sales, with market price at 1590.4249877929688 per share.During the period under consideration, there were no sell transactions.The recent trend of increased buying at CIPLA's current price levels may indicate a favorable market sentiment. This could point to a positive outlook for the stock, as investors show growing confidence through higher buy activity.

Recommendation changes over time:

Recommendations trend for CIPLA
Recommendations trend for CIPLA


Recent analysis shows a strong buy bias for CIPLA, encouraging investors to view it as a solid investment option. The positive sentiment surrounding CIPLA suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.